2022 World Conference on Lung Cancer (ePosters)-EP08.01-102. Anlotinib Combined with PD-1 Inhibitors May Benefit Advanced Non-small Cell Lung Cancer Patients After Failure of EGFR-TKI Therapy

EP08.01-102. Anlotinib Combined with PD-1 Inhibitors May Benefit Advanced Non-small Cell Lung Cancer Patients After Failure of EGFR-TKI Therapy

Back to course

Pdf Summary

A study conducted at Shanghai Chest Hospital in China suggests that treating patients with advanced non-small cell lung cancer (NSCLC) who have failed EGFR-TKI therapy with a combination of anlotinib and PD-1 inhibitors may be beneficial. The study included 38 patients with EGFR-TKI resistance who were treated with the combination therapy. The median progression-free survival was 4.33 months, and the median overall survival was 11.83 months. Most of the patients received the combination therapy in the fourth or later lines of treatment. The disease control rate was 92.1%. Adverse events such as asthenia, poor appetite, and oral ulcers were manageable and reversible, with only three patients discontinuing the therapy due to adverse events. The researchers concluded that the combination of anlotinib and PD-1 inhibitors holds promise as a late-line treatment for NSCLC patients with EGFR-TKI resistance and further validation is needed in prospective trials. This study adds to the limited treatment options for NSCLC patients with EGFR-TKI resistance, which is a significant challenge in the management of these patients.

Asset Subtitle

Lian Yu

Meta Tag

Speaker Lian Yu

Topic Metastatic Non-small Cell Lung Cancer - Immunotherapy

Keywords

non-small cell lung cancer

NSCLC

EGFR-TKI therapy

anlotinib

PD-1 inhibitors

combination therapy

progression-free survival

overall survival

disease control rate

late-line treatment